MYC and neoplasm: Clinical testing of an MYC-derived therapeutic protein is exciting, but it might be difficult to deliver macromolecules to tumours in organs such as the brain and pancreas.19 Indeed, protein-based drugs have more limited drug-delivery properties compared with small-molecule drugs, but so far no small-molecule inhibitor of MYC has advanced to clinical testing for various reasons.